Canada Proposes to Amend Drug Pricing Regulations
By Zachary Brennan -
Published 17 May 2017
For the first time in more than two decades, Canada’s government is looking to amend its drug pricing regulations to better protect Canadians from paying excessive prices for patented drugs.
Categories: News, Canada, US, FDA, Health Canada, NICE, Biologics and biotechnology, Drugs, Regulatory intelligence, Regulatory strategy, Research and development
Tags: drug pricing, Canada drug prices, QALY, PMPRB, generic drugmakers